ArticleJournal of asthma and allergy2021
Optimal Management of Hereditary Angioedema: Shared Decision-Making.
Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Garadacimab in Hereditary Angioedema: Modeling Suggests Sustained Improvements in Attack-Free Probability and Quality of Life Over 5 Years.Clinical and translational science · 2026Trial
- Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema.Clinical and translational allergy · 2026Article
- Long-term prophylactic treatment and related real-world outcomes of patients with hereditary angioedema in Germany: A retrospective analysis of German claims and medical chart data.The World Allergy Organization journal · 2026Article
- Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.The World Allergy Organization journal · 2026Review
- Optimizing conversations on treatment management in hereditary angioedema: healthcare professional and patient perspectives on long-term prophylaxis and shared decision-making.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.The World Allergy Organization journal · 2026Article
- The International/Canadian hereditary angioedema guideline.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Review
- Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care.Allergologie select · 2026Article
- Achieving a normal life in hereditary angioedema: Quality of life and treatment gaps among German HAE patients.Allergologie select · 2026Article
- A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.Frontiers in immunology · 2026Article
- Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Erratum: Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.Journal of health economics and outcomes research · 2025Article
- The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series.Orphanet journal of rare diseases · 2024Article
- [Hereditary angioedema due to C1-inhibitor deficiency, a national disease management programme].Wiener klinische Wochenschrift · 2023Article
- Patient-physician interactions in hereditary angioedema-Key learnings from the coronavirus disease 2019 pandemic.Clinical and translational allergy · 2023Review
- Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review.Clinical and translational allergy · 2023Review
- The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.The World Allergy Organization journal · 2022Article
- Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.Drug, healthcare and patient safety · 2022Review
- Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema.Clinical and translational allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
All patients with hereditary angioedema (HAE) must have access to on-demand therapy to treat attacks and may benefit from prophylactic therapy to reduce the attack frequency. Treatment decisions should be individualized, based on patient preferences and needs. One method for facilitating individualized therapy is shared decision-making (SDM), a widely used methodology for making treatment decisions among multiple therapeutic options. We propose a three-phase "3D" model (Discover, Discuss, Decide) for SDM in HAE. The Discover phase focuses on improving the physician's understanding of the patient's needs and understanding of the available therapeutic choices. The Discuss phase considers the alternatives, allowing a collaborative, informed treatment selection in the Decision phase. The 3D model is an ongoing, iterative process based on the patient's changing needs and response to therapy. Uncovering the patient's therapy goals through appropriate questions during these phases can help uncover relevant information for treatment selection information. SDM based on the 3D model can be a beneficial tool for optimizing therapy in HAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.